Type 2 Diabetes Clinical Trial
Official title:
Randomized Controlled Trial to Evaluate the Efficacy of an Integrated Lifestyle Management Solution With Continuous Glucose Monitoring for Type 2 Diabetes
Verified date | April 2024 |
Source | Omada Health, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to examine the efficacy of an integrated solution, defined as a combination of the Abbott FreeStyle Libre 14-day CGM sensor and the Omada care team's receipt of real-time, continuous glucose data from the sensor and incorporation of this data into their care delivery within the context of the Omada for Diabetes program for adults with Type 2 Diabetes (T2D). This randomized control trial will test the impact of the integrated solution on HbA1c, CGM-derived metrics and other relevant diabetes management outcomes over six months compared to the current standard of care.
Status | Completed |
Enrollment | 100 |
Est. completion date | January 24, 2024 |
Est. primary completion date | January 24, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | INCLUSION CRITERIA 1. 18 years or older 2. Lives in the United States and has a valid mailing address 3. Speaks, reads, and understands English as the primary language 4. Be willing and able to provide written, signed, and dated informed consent 5. Has a self-reported diagnosis of type 2 diabetes prior to enrollment for at least 6 months 6. Self-reports HbA1c value =8.0% from most recent test taken within the past 6 months 7. Treatment regimen includes diet and exercise alone, oral glucose lowering medication, non-insulin injectable medications, basal insulin and/or combination of basal insulin plus oral medications. No more than 15% of the total sample may be on combination basal insulin/oral medication. a. If the regimen is basal insulin with oral medications, the participant must have initiated basal insulin in addition to oral medication at least 6 months prior to enrollment. 8. Currently on medication regimen for at least 3 months prior to enrollment 9. HbA1c greater than or equal to 8.0% as demonstrated by laboratory HbA1c at secondary screening 10. Has a compatible smartphone running either Android OS 5.0 or higher, or iPhone 7 or later, running iOS 11 or higher with an on-going data plan 11. Is willing to set up an online account using the Omada Health Program/app and LibreLink app, and agree to share their CGM data with designated health care providers connected to the study. 12. Must be willing to complete all study tasks as specified by the protocol 13. Must report being compliant with their diabetes management plan and must be willing to adhere to their medication regimen throughout the study. 14. Not currently in another clinical trial EXCLUSION CRITERIA 1. Type 1 diabetes or a history of diabetic ketoacidosis 2. Self-reported HbA1c < 8.0% or does not know their HbA1c level 3. Self-reported condition leading to life expectancy < 12 months 4. Pregnant, is attempting to conceive or is not willing and able to practice birth control during the study duration (applicable to female participants who are able to become pregnant only) 5. Currently has self-reported skin lesions, scarring, redness, infection or edema at the application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. This includes known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin 6. Has X-ray, MRI or CT appointment scheduled during the study periods of CGM measurement with the FreeStyle Libre Pro, and the appointment(s) cannot be rescheduled 7. Currently using mealtime bolus injections of insulin, premixed insulin formulations or a continuous subcutaneous infusion of insulin 8. Visual impairment that would prohibit ability to view sensor data or use the Omada platform 9. Has had any of the following in the past 3 months: - Transient ischemic attack or stroke - Heart attack (myocardial infarction) - Hospitalization for congestive heart failure - Cardiac surgery (such as coronary artery bypass grafting (CABG), coronary artery stenting) - If it has been > 3 months since any of the above, applicant must be medically cleared by their primary physician to exercise 10. Bariatric/gastric bypass surgery, including gastric sleeve, gastric balloon within the past 6 months 11. Participation in other research studies involving medication or device within 1 month prior to enrollment 12. Organ transplant (kidney, liver, etc.) within the past 6 months 13. Recent (within the last 6 months) or planned cancer treatment (chemotherapy, radiation, bone marrow transplant, cancer-related surgery - not including hormonal chemotherapy, such as tamoxifen) 14. Self-reported renal impairment, defined as estimated glomerular filtration rate <30 mL/min/1.73 m2 15. Language barriers precluding comprehension of study activities and informed consent 16. Currently on a routine regimen of glucocorticoids or psychotropic medications 17. Self-reported alcohol or substance abuse issue or dependency |
Country | Name | City | State |
---|---|---|---|
United States | Evidation Health | San Mateo | California |
Lead Sponsor | Collaborator |
---|---|
Omada Health, Inc. | Abbott Diabetes Care, Evidation Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in HbA1c | Non-fasting venous blood sample | Baseline, 3 months, 6 months | |
Secondary | Change in daily Time in Range [70-180] mg/dL | Derived from continuous glucose monitor | Baseline, 3 months, 6 months | |
Secondary | Change in body weight | Measured with a digital weight scale in stocking feet | Baseline, 3 months, 6 months | |
Secondary | Change in resting blood pressure | Collected with an automated, calibrated blood pressure monitor with self-inflating cuff | Baseline, 3 months, 6 months | |
Secondary | Change in diabetes distress | The Diabetes Distress Scale, a 17-item self-report questionnaire, that captures four dimensions: emotional burden, regimen distress, interpersonal distress and physician distress related to diabetes and diabetes self-care | Baseline, 3 months, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |